This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and
tolerability of intratumoral (IT) injection of ANK-101 in participants with advanced solid
tumors who have progressed during or after receiving standard of care (SOC) therapy or who
will not benefit from such therapy. The study will be conducted in two parts; Part 1 will
enroll participants with superficial lesions and Part 2 will enroll participants with
visceral lesions.